Physician profile
Vicki C Van
NPI 1124181086
$8,857.97
in general payments reported to CMS, 2019-2025
42 companies · $1,682 in 2025
The $1,682 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,077 · 2020: $734 · 2021: $1,007 · 2022: $1,140 · 2023: $1,579 · 2024: $1,639 · 2025: $1,682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,900.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,480.76 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,042.70 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $815.81 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $723.84 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $709.75 | 2019-2025 | |
| Novo Nordisk INC | $662.86 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $598.65 | 2019-2025 | Otezla, Repatha, Repatha |
| Otsuka America Pharmaceutical, INC. | $395.05 | 2021-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $244.52 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $221.13 | 2022-2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $184.20 | 2019-2023 | Xifaxan, Trulance |
| Astellas Pharma US INC | $161.42 | 2019-2024 | Veozah |
| Lundbeck LLC | $147.66 | 2024-2025 | Rexulti |
| Exact Sciences Corporation | $129.22 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Allergan, INC. | $124.77 | 2019-2020 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vicki Van listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.